Oncocyte to Participate at Needham Virtual Cancer Diagnostics Conference
Oncocyte Corporation (NYSE American: OCX) will engage in 1-on-1 meetings at the Needham Virtual Cancer Diagnostics 1x1 Conference on August 18, 2020.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Oncocyte Corporation (NYSE American: OCX) will engage in 1-on-1 meetings at the Needham Virtual Cancer Diagnostics 1x1 Conference on August 18, 2020. The company specializes in molecular diagnostics aimed at enhancing cancer care. Their launched test, DetermaRx, identifies early-stage lung cancer patients at high risk for recurrence, optimizing treatment through timely adjuvant chemotherapy. Additionally, they are developing DetermaIO, which assesses patient response to immunotherapies. These innovations aim to improve patient outcomes significantly.
Details
News Market Reaction – OCX
The recorded move for OCX in the trading session of this news was -0.57%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
IRVINE, Calif., Aug. 13, 2020 (GLOBE NEWSWIRE) -- Oncocyte Corporation (NYSE American: OCX), a molecular diagnostics company with a mission to provide actionable answers at critical decision points across the cancer care continuum, today announced that company management will participate in the 1-on-1 meetings at the upcoming Needham Virtual Cancer Diagnostics 1x1 Conference on Tuesday, August 18, 2020.
About Oncocyte Corporation
Oncocyte is a molecular diagnostics company whose mission is to provide actionable answers at critical decision points across the cancer care continuum, with the goal of improving patient outcomes by accelerating and optimizing diagnosis and treatment. The Company recently launched DetermaRx™, a treatment stratification test that enables the identification of early-stage lung cancer patients at high risk for recurrence post-resection, allowing them to be treated when their cancer may be more responsive to adjuvant chemotherapy. Oncocyte is also developing DetermaIO™, a gene expression test that identifies patients more likely to respond to checkpoint immunotherapies.
DetermaRx and DetermaIO are trademarks of Oncocyte Corporation.
Investor Contact
Bob Yedid
LifeSci Advisors, LLC
646-597-6989
bob@lifesciadvisors.com
Media Contact
Cait Williamson, Ph.D.
LifeSci Communications, LLC
646-751-4366
cait@lifescicomms.com
Source: Oncocyte Corporation
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.